A brief, evidence-based overview of a cancer of the ovary and its latest developments.
Johnson & Johnson has reached a landmark settlement to resolve about 76,000 talc-related claims alleging ovarian cancer, potentially ending a decade-long legal battle. The deal requires 95% court acceptance and could total well above $3 billion, with payments beginning in 2027 and continuing into 2028; total payout could rise to $7 billion or more depending on participation.
Johnson & Johnson has reached a settlement to resolve tens of thousands of talc-related claims. The deal covers about 76,000 claims, with initial payments of up to $3 billion next year and further payments in 2028, subject to 95% claimant participation. The agreement aims to end a decade-long court battle over asbestos-tainted talc products, while preserving the company’s broader mission to develop medicines and devices.